FERRARO, Diana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.655
EU - Europa 3.287
AS - Asia 1.580
SA - Sud America 33
OC - Oceania 28
AF - Africa 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 15.589
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.607
GB - Regno Unito 1.399
SG - Singapore 517
IT - Italia 461
CN - Cina 417
SE - Svezia 364
HK - Hong Kong 334
DE - Germania 275
UA - Ucraina 166
FI - Finlandia 143
BG - Bulgaria 116
RU - Federazione Russa 114
TR - Turchia 108
FR - Francia 101
ID - Indonesia 58
CA - Canada 37
KR - Corea 35
AU - Australia 27
IR - Iran 24
IN - India 22
CZ - Repubblica Ceca 21
IE - Irlanda 21
BE - Belgio 19
BR - Brasile 18
NL - Olanda 16
JP - Giappone 15
PL - Polonia 13
CH - Svizzera 12
MY - Malesia 11
BZ - Belize 10
AT - Austria 9
CL - Cile 8
LT - Lituania 7
ES - Italia 6
BD - Bangladesh 5
DK - Danimarca 4
GR - Grecia 4
QA - Qatar 4
AE - Emirati Arabi Uniti 3
AR - Argentina 3
GE - Georgia 3
IL - Israele 3
NO - Norvegia 3
PH - Filippine 3
PK - Pakistan 3
RO - Romania 3
SA - Arabia Saudita 3
EU - Europa 2
HU - Ungheria 2
IQ - Iraq 2
LK - Sri Lanka 2
LU - Lussemburgo 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
VN - Vietnam 2
AZ - Azerbaigian 1
CO - Colombia 1
EC - Ecuador 1
EG - Egitto 1
GH - Ghana 1
HR - Croazia 1
IM - Isola di Man 1
JO - Giordania 1
KH - Cambogia 1
KZ - Kazakistan 1
MX - Messico 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PE - Perù 1
SN - Senegal 1
UY - Uruguay 1
Totale 15.589
Salva come PNG Salva come JPEG
Città #
Fairfield 1.818
Santa Clara 1.284
Southend 1.203
Woodbridge 872
Ashburn 821
Seattle 708
Houston 690
Chandler 619
Cambridge 604
Wilmington 532
Singapore 388
Ann Arbor 353
Hong Kong 332
Dearborn 317
Jacksonville 285
Nyköping 280
Modena 151
San Diego 138
Helsinki 119
Princeton 118
Sofia 116
New York 107
Beijing 73
Eugene 73
Jakarta 58
London 56
Bremen 46
Izmir 44
Moscow 42
Redwood City 42
Norwalk 39
Shanghai 32
Munich 31
Boardman 30
Fremont 25
Seongnam 23
Dublin 21
Milan 19
Falls Church 18
Guangzhou 18
Kunming 18
Brussels 17
Hefei 17
Piacenza 16
Kilburn 15
Toronto 15
Phoenix 14
Prescot 14
Edinburgh 13
Paris 13
Olomouc 12
Chiswick 11
Frankfurt am Main 11
Nanjing 11
Belize City 10
Andover 9
Chicago 9
Ottawa 9
Rome 9
Washington 9
Des Moines 8
Serramazzoni 8
Zanjan 8
Acton 7
Bologna 7
Hounslow 7
Las Vegas 7
Parma 7
Rimini 7
San Francisco 7
San Jose 7
Vienna 7
Amsterdam 6
Leawood 6
Los Angeles 6
Nanchang 6
Seoul 6
Brno 5
Hebei 5
Jinan 5
Melbourne 5
Polska 5
Reggio Emilia 5
Wuhan 5
Berlin 4
Buffalo 4
Dallas 4
Dongguan 4
Islington 4
Istanbul 4
Sacramento 4
Senigallia 4
Zhengzhou 4
Aberdeen 3
Athens 3
Atlanta 3
Bangalore 3
Benevento 3
Brescia 3
Buenos Aires 3
Totale 13.006
Salva come PNG Salva come JPEG
Nome #
Definitive childlessness in women with multiple sclerosis: a multicenter study 575
Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: Association with oligoclonal IgM bands and prediction of Multiple Sclerosis diagnosis 300
iNKT cells in secondary progressive multiple sclerosis patients display pro-inflammatory profiles 268
Aging with HIV infection: a journey to the center of inflammAIDS, immunosenescence and neuroHIV 262
Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: Results from an observational study 237
A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band 236
A quantitative comparison of BOLD fMRI responses to noxious and innocuous stimuli in the human spinal cord 231
Cerebrospinal fluid anti-Epstein-Barr virus specific oligoclonal IgM and IgG bands in patients with clinically isolated and Guillain-Barré syndrome 229
Amyotrophic lateral sclerosis: a comparison of two staging systems in a population-based study 222
"Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study 220
Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with Clinically Isolated Syndrome. 213
Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study 213
Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study 210
Acute hemichorea as unusual first multiple sclerosis presentation 209
Invariant natural killer T cells and mucosal-associated invariant T cells in multiple sclerosis 209
Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM 205
Methylprednisolone-induced toxic hepatitis after intravenous pulsed therapy for multiple sclerosis relapses 205
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis 201
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis 199
Changing incidence and subtypes of ALS in Modena, Italy: A 10-years prospective study 198
Recurrent varicella following steroids and fingolimod in a Multiple Sclerosis patient 193
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS 193
Isolated progressive cognitive impairment and depression in a patient with neuroradiological features suggestive of multiple sclerosis 187
Semiautomated segmentation of the human spine based on echoplanar images 186
Mitochondrial functionality and metabolism in T cells from progressive multiple sclerosis patients 185
Frequent early multiple sclerosis relapses during treatment with fingolimod: a paradoxical effect? 185
Severe anemia in a patient with multiple sclerosis treated with natalizumab 184
False positive absent somatosensory evoked potentials in cardiac arrest with therapeutic hypothermia. 184
Antiepileptic drugs in the treatment of headache: Neuroprotective effect or something else? 183
Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor? 183
Cerebrospinal fluid amounts of HLA-G in dimeric form are strongly associated to patients with MRI inactive multiple sclerosis 182
First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistence 178
Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis 176
Mitochondrial damage-associated molecular patterns stimulate reactive oxygen species production in human microglia 176
Charcot-Marie-Tooth and pain: Correlations with neurophysiological, clinical, and disability findings 174
Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients 174
Abnormal Circadian Modification of Aδ-Fiber Pathway Excitability in Idiopathic Restless Legs Syndrome 174
Increased plasma levels of mitochondrial DNA and pro-inflammatory cytokines in patients with progressive multiple sclerosis 173
Diagnostics of dysimmune peripheral neuropathies 172
Acute necrotizing encephalopathy: A relapsing case in a European adult [4] 171
Topiramate in the prevention of pediatric migraine: Literature review 171
Serum IgG against Simian Virus 40 antigens are hampered by high levels of sHLA-G in patients affected by inflammatory neurological diseases, as multiple sclerosis 170
The abnormal recovery cycle of somatosensory evoked potential components in children with migraine can be reversed by topiramate 170
Systematic assessment and characterization of chronic pain in multiple sclerosis patients 169
Antiepileptic drugs in the preventive treatment of migraine in children and adolescents 169
Letter to Editor: Carpal tunnel syndrome due to an atypical deep soft tissue leiomyoma: The risk of misdiagnosis and mismanagement 168
Diagnostics of anti-MAG antibody polyneuropathy 168
Paroxysmal ventricular tachicardia and pure right insular stroke 167
TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis 163
Cerebrospinal fluid kappa and lambda free light chains in oligoclonal band‐negative patients with suspected multiple sclerosis 161
Percutaneous endoscopic gastrostomy, body weight loss and survival in amyotrophic lateral sclerosis: a population-based registry study 159
Left thalamomegaly in a patient with partial epilepsy 159
Mechanisms of neuropathic pain in patients with Charcot-Marie-Tooth 1 A: A laser-evoked potential study 158
Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine 157
Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study 157
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis 152
Multiple attack study on the available triptans in Italy versus placebo 151
Topiramate in migraine prophylaxis: A randomised double-blind versus placebo study 149
Evidence of different spinal pathways for the warmth evoked potentials 148
Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: Acetylcholinesterase activity cannot be considered a useful biomarker 147
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis 146
The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study 146
Habituation to Pain in "Medication Overuse Headache": A CO2 Laser-Evoked Potential Study 143
Occupational head injury and subsequent glioma 137
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study 135
Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy 128
Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study 126
Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study) 125
Risk of secondary progressive multiple sclerosis: A longitudinal study 124
Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis 122
Kappa Index Versus CSF Oligoclonal Bands in Predicting Multiple Sclerosis and Infectious/Inflammatory CNS Disorders 120
Conversion to secondary progressive multiple sclerosis: Patient awareness and needs. Results from an online survey in Italy and Germany 113
Simultaneous quantification of natural and inducible regulatory T-cell subsets during interferon-β therapy of multiple sclerosis patients 112
Treatment response score to glatiramer acetate or interferon beta-1a 110
Antiepileptic drugs in migraine prophylaxis: state of the art 109
Informing MS patients on treatment options: a consensus on the process of consent taking 97
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder 96
Inter-center agreement in the interpretation of oligoclonal bands 96
Association of Sustained Immunotherapy with Disability Outcomes in Patients with Active Secondary Progressive Multiple Sclerosis 94
A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia 87
Acute hemichorea as unusual first multiple sclerosis presentation: two case reports 84
Diagnostic features of initial demyelinating events associated with serum MOG-IgG 82
A voxel-based lesion symptom mapping analysis of chronic pain in multiple sclerosis 81
Microglia activation: A role for mitochondrial DNA? 80
Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing–remitting multiple sclerosis 79
Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, Italy 72
Modulation of tregs and inkt by fingolimod in multiple sclerosis patients 68
A novel SOD1 mutation in a young ALS patient associated with slowly progressive clinical course 67
Cell-based assays for the detection of MOG antibodies: a comparative study 66
Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group 65
Early clinical markers of aggressive multiple sclerosis 62
Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score 62
Efficacy of mechanical thrombectomy in patients with ischemic stroke and cancer 62
A study of the CD45 exon 4 C77G polymorphism in a patient affected both by multiple sclerosis and pulmonary Langerhans' cell histiocytosis 61
Serum neurofilament light as biomarker of seizure-related neuronal injury in status epilepticus 58
Delay from treatment start to full effect of immunotherapies for multiple sclerosis 57
Slowly progressive ALS associated with a novel SOD1 D11Y mutation 52
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors 51
Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS 50
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 49
Totale 15.342
Salva come PNG Salva come JPEG
Categoria #
all - tutte 74.253
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 74.253
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.804 0 0 0 0 0 0 592 386 387 160 172 107
2020/20213.223 230 200 294 312 481 193 186 371 164 428 224 140
2021/20222.344 216 274 249 93 40 134 107 140 246 222 393 230
2022/20231.721 195 202 145 179 197 246 21 185 187 12 102 50
2023/20241.218 33 70 60 157 223 106 145 154 28 14 60 168
2024/20252.202 149 37 45 319 904 699 49 0 0 0 0 0
Totale 15.789